

48R 0004

W. A. Christensen, DVM  
United States Department of Agriculture  
Animal and Plant Health Inspection Service  
Animal Care  
501 Felix, Building 11  
Fort Worth, Texas 76115-6258  
(817) 885-6923

October 1, 1999

Dear Dr. Christensen:

The following information is submitted in fulfillment of requirement for submission of the Annual Report of Research Facility for Bayer Corporation Research Facility, registration number **48-R-004**. The VS Form 18-23 with signatures is attached.

#### **ASSURANCE STATEMENTS**

- 1 Professionally acceptable standards governing the care, treatment, and use of animals, including the appropriate use of anesthetic, analgesic, and tranquilizing drugs, prior to, during, and following actual research, teaching, testing, or experimentation were followed by the Bayer Corporation Research Facility and monitored by the Institutional Animal Care and Use Committee (IACUC).
- 2 Each principal investigator has considered alternatives to painful procedures. We perform tests in accordance with standards and guidelines outlined by the Environmental Protection Agency and the Food and Drug Agency regulations.
- 3 The facility is adhering to the standards of the Act, and that it has required that exceptions to the standards and regulations be specified and explained by the principal investigator and approved by the IACUC. A summary of all such exceptions must be attached to the facility's annual report. In addition to identifying the IACUC-approved exceptions, this summary must include a brief explanation of the exceptions, as well as the species and number of animals affected. We have no exceptions to the standards and regulations of the Act.

The facility is Accredited by the American Association for Accreditation of Laboratory Animal Care and has been fully accredited since 1981. Our most recent site visit was October 28, 1998.

**STATEMENT OF LOCATION**

4 State the location of all facilities where animals were housed or used in actual research, testing, teaching or experimentation, or held for these purposes: Bayer Corporation Research Facility, Registration Number **48-R-004**, Toxicology Building, Bayer Research Park, 17745 South Metcalf, Stilwell, Kansas, 66085-9104.

**STATEMENTS OF ANIMAL USE**

5 State the common names and the numbers of animals upon which teaching, research, experiments or tests were conducted involving no pain, distress, or use of pain-relieving drugs. Routine procedures (e.g. injections, tattooing, blood sampling) are reported with this group.

**Dogs**                      **324**

**Rats**                      **9590**

**Mice**                      **2830**

6 State the common names and the numbers of animals upon which teaching, research, experiments or tests were conducted involving accompanying pain or distress to the animals and for which appropriate anesthetic, analgesic, or tranquilizing drugs were used.

**Rats**                      **168**

All procedures involving animal use within this facility are reviewed and approved by the Institutional Animal Care and Use Committee.

7 State the common names and the numbers of animals upon which teaching, research, experiments or tests were conducted involving accompanying pain or distress to the animals and for which the use of the appropriate anesthetic, analgesic, or tranquilizing drugs would have adversely affected the procedures, results, or interpretation of the teaching, research, experiments, surgery, or tests. An explanation of the procedures producing pain or distress in these animals and the reasons such drugs were not used shall be attached to the annual report.

Animals are used for toxicological studies required by the FDA and EPA. The use of anesthetic, analgesic, or tranquilizing drugs would interfere with test results. Common types of toxicity tests we perform including oral dosing, dermal exposure and inhalation exposure, may cause periodic distress during the course of the test. All procedures involving animal use within this facility are reviewed and approved by the Institutional Animal Care and Use Committee prior to the initiation of the procedure.